

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|-----------|---|------------------------------|---|---------------------|
| Applicant | : | Weiner, et al. |) | Group Art Unit 1617 |
| | | |) | |
| App. No. | : | 10/759,561 |) | |
| | | |) | |
| Filed | : | January 15, 2004 |) | |
| | | |) | |
| For | : | SELECTIVE SEROTONIN 2A/2C |) | |
| | | RECEPTOR INVERSE AGONISTS AS |) | |
| | | THERAPEUTICS FOR |) | |
| | | NEURODEGENERATIVE DISEASES |) | |
| | | |) | |
| Examiner | : | Leonard M. Williams |) | |

REQUEST TO CORRECT INVENTORSHIP

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication is a request to correct the original naming of inventors under 37 C.F.R. § 1.48 as set forth in the original declaration filed on June 21, 2004 in the above-named application.

Please add the following person as an inventor of this application.

Norman Nash
10994 W. Ocean Air Drive #384
San Diego, CA 92130

Attached is the Statement of Norman Nash under 37 C.F.R. § 1.48(a)(2) that the error in inventorship occurred without deceptive intention on his part, a new declaration by the actual inventors pursuant to 37 C.F.R. § 1.48(a)(3), and the written consent of the assignee pursuant to 37 C.F.R. § 1.48(a)(5).

Appl. No. : 10/759,561
Filed : January 15, 2004

The required fee payment (37 C.F.R. § 1.1.17(i)) is enclosed. Please charge any additional fees to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7-13-07

By: Ryan E. Melnick
Ryan E. Melnick
Registration No. 58,621
Attorney of Record
Customer Number 20,995
(619) 235-8550

4010601:sad
071307

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Weiner, et al.
Appl. No. : 10/759,561
Filed : January 15, 2004
For : SELECTIVE SEROTONIN 2A/2C
RECEPTOR INVERSE
AGONISTS AS THERAPEUTICS
FOR NEURODEGENERATIVE
DISEASES
Examiner : Leonard M. Williams
Group Art Unit : 1617

STATEMENT OF NORMAN NASH UNDER 37 C.F.R. § 1.48(a)(2)

Mailstop Petitions
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Norman Nash, am an inventor of subject matter claimed in the above-referenced patent application. The failure to include my name as an inventor was an error that occurred without any deceptive intent on my part.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardized the validity of the application or patent issuing therefrom.

Respectfully submitted,

Dated: 1/2/2007

By: 

Norman Nash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|----------------|---|--|
| Applicant | : | Weiner, et al. |
| Appl. No. | : | 10/759,561 |
| Filed | : | January 15, 2004 |
| For | : | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES |
| Examiner | : | Leonard M. Williams |
| Group Art Unit | : | 1617 |

CONSENT OF ASSIGNEE UNDER 37 U.S.C., § 1.48(a)(5) TO ADD INVENTOR

The undersigned is empowered to act on behalf of the Assignee of the above-named application, Acadia Pharmaceuticals Inc. ("Assignee"). The Assignee represents that it is the 100% owner by assignment of the above-referenced application by virtue of the assignments recorded at Reel No. 015548, Frame No. 0274 by the Assignment Branch of the Patent and Trademark Office. The Assignee hereby consents to the addition of the following inventor:

Norman Nash
3752 Mykonos Lane, Unit 105
San Diego, CA 92130

Dated: April 27, 2007

By: Uli Hacksell
Print Name


Signed